**2025 Pediatric ICD-10-CM Codes**

***Effective October 1, 2024***

The 2025 changes to ICD-10-CM become effective on October 1, 2024. Listed below are the new codes we believe are of most interest to pediatricians. Please see your 2025 ICD-10-CM code book for a complete list of changes and to verify all new and revised codes.

**Chapter 4 Endocrine, nutritional and metabolic diseases**

**E08.xx** Diabetes mellitus due to underlying condition

(Use Additional code for injectable non-insulin antidiabetic drugs (**Z79.85**)

**E08.64** Diabetes mellitus due to underlying condition with hypoglycemia Use Additional code for hypoglycemia level, if applicable (**E16.Ax**)

**E09.xx** Drug or chemical induced diabetes mellitus

(Use Additional code for injectable non-insulin antidiabetic drugs (**Z79.85**)

**E09.64** Drug or chemical induced diabetes mellitus with hypoglycemia Use Additional code for hypoglycemia level, if applicable (**E16.Ax**)

**E10.Ax** Type 1 diabetes mellitus, presymptomatic Early stage type 1 diabetes mellitus

**E10.A0** Type 1 diabetes mellitus, presymptomatic, unspecified

**E10.A1** Type 1 diabetes mellitus, presymptomatic, Stage 1 Multiple confirmed islet autoantibodies with normoglycemia

**E10.A2** Type 1 diabetes mellitus, presymptomatic, Stage 2 Confirmed islet autoimmunity with dysglycemia

**E11.xx** Type 2 Diabetes Mellitus

(Use Additional code for injectable non-insulin antidiabetic drugs (**Z79.85**)

**E11.64** Type 2 Diabetes Mellitus with hypoglycemia

Use Additional code for hypoglycemia level, if applicable (**E16.Ax**)

**E13.xx** Other Specified Diabetes Mellitus

(Use Additional code for injectable non-insulin antidiabetic drugs (**Z79.85**)

**E13.64** Other specified diabetes mellitus with hypoglycemia

Use Additional code for hypoglycemia level, if applicable (**E16.Ax**)

**E16.Ax** Hypoglycemia level

**E16.A1** Hypoglycemia level 1 Decreased blood glucose level 1

**E16.A2** Hypoglycemia level 2 Decreased blood glucose level 2

**E16.A3** Hypoglycemia level 3 Decreased blood glucose level 3

**E16.1** Other hypoglycemia

(Use Additional code for hypoglycemia level, if applicable(**E16.Ax**)

**E16.2** Hypoglycemia, unspecified

(Use Additional code for hypoglycemia level, if applicable(**E16.Ax**)

**E66.xx** Overweight and Obesity

(Use Additional code to identify body mass index (BMI), if known, for adults (**Z68.1-Z68.45**) or pediatrics(**Z68.5x)**

**E66.811** Obesity, class 1

**E66.812** Obesity, class 2

**E66.813** Obesity, class 3

**E66.89** Other obesity not elsewhere classified

**Chapter 5 Mental, Behavioral and Neurodevelopmental disorders**

**F20.x** Schizophrenia

Use additional code if applicable to identify other specified cognitive deficit **(R41.84x)**

**F50.01x** Anorexia nervosa, restricting type

**F50.010** Anorexia nervosa, restricting type, mild Anorexia nervosa, restricting type, with a body mass index greater than or equal to17 kg/m2

**F50.011** Anorexia nervosa, restricting type, moderate Anorexia nervosa, restricting type, with a body mass index of 16.0-16.99 kg/m2

**F50.012** Anorexia nervosa, restricting type, severe Anorexia nervosa, restricting type, with a body mass index of 15.0-15.99 kg/m2

**F50.013** Anorexia nervosa, restricting type, extreme Anorexia nervosa, restricting type, with a body mass index of less than 15.0 kg/m2

**F50.014** Anorexia nervosa, restricting type, in remission Anorexia nervosa, restricting type, in full remission Anorexia nervosa, restricting type, in partial remission

**F50.019** Anorexia nervosa, restricting type, unspecified

**F50.02x** Anorexia nervosa, binge eating/purging type

**F50.020** Anorexia nervosa, binge eating/purging type, mild Anorexia nervosa, binge eating/purging type, with a body mass index greater than or equal to 17 kg/m2

**F50.021** Anorexia nervosa, binge eating/purging type, moderate Anorexia nervosa, binge eating/purging type, with a body mass index of 16.0- 16.99kg/m2

**F50.022** Anorexia nervosa, binge eating/purging type, severe Anorexia nervosa, binge eating/purging type, with a body mass index of 15.0-15.99kg/m2

**F50.023** Anorexia nervosa, binge eating/purging type, extreme Anorexia nervosa, binge eating/purging type, with a body mass index of less than15.0 kg/m2

**F50.024** Anorexia nervosa, binge eating/purging type, in remission Anorexia nervosa, binge eating/purging type, in full remission Anorexia nervosa, binge eating/purging type, in partial remission

**F50.029** Anorexia nervosa, binge eating/purging type, unspecified

**F50.2x** **Bulimia Nervosa**

**F50.20** Bulimia nervosa, unspecified

**F50.21** Bulimia nervosa, mild Bulimia nervosa with 1-3 episodes of inappropriate compensatory behavior per week

**F50.22** Bulimia nervosa, moderate Bulimia nervosa with 4-7 episodes of inappropriate compensatory behavior per week

**F50.23** Bulimia nervosa, severe Bulimia nervosa with 8-13 episodes of inappropriate compensatory behavior per week

**F50.24** Bulimia nervosa, extreme Bulimia nervosa with 14 or more episodes of inappropriate compensatory behavior per week

**F50.25** Bulimia nervosa, in remission

Bulimia nervosa, in full remission

Bulimia nervosa, in partial remission

**F50.8 Other Eating Disorders**

**F50.83** Pica in adults Pica in adults, in remission

Excludes1: pica in infancy and childhood **(F98.3)**

**F50.84** Rumination disorder in adults Rumination disorder in adults, in remission

Excludes1: rumination disorder in infancy and childhood **(F98.21)**

**Chapter 6 Diseases of the Nervous System**

**G40.8xx** Other Epilepsy and Recurrent Seizures

**G40.84x** KCNQ2-related epilepsy

**G40.841** KCNQ2-related epilepsy, not intractable, with status epilepticus

**G40.842** KCNQ2-related epilepsy, not intractable, without status epilepticus KCNQ2-related epilepsy NOS

**G40.843** KCNQ2-related epilepsy, intractable, with status epilepticus **G40.844** KCNQ2-related epilepsy, intractable, without status epilepticus

**G90.81** Serotonin syndrome Serotonin toxicity

**Code first** poisoning due to drug or toxin, such as:

linezolid (T36.8x- with sixth character 1-4)

monoamine oxidase inhibitors (T43.1x with sixth character )

selective serotonin and norepinephrine reuptake inhibitors [SSNRI] (T43.21with sixth character 1-4)

selective serotonin reuptake inhibitors [SSRI] (T43.22 with sixth character 1-4)

**Use Additional** code for adverse effect, if applicable, to identify drug, such as:

linezolid (T36.8x5) monoamine oxidase inhibitors (T43.1x5)

selective serotonin and norepinephrine reuptake inhibitors [ SSNRI](T43.215)

selective serotonin reuptake inhibitors [SSRI] (T43.225)

**Use Additional** code, if applicable, to identify:

disseminated intravascular coagulation (D65)

hypertensive crisis (I16.x)

metabolic acidosis (E87.x-)

shock, not elsewhere classified (R57.x)

toxic encephalopathy (G92.x)

ventricular tachycardia (I47.2x)

**G93.45** Developmental and epileptic encephalopathy

Early infantile epileptic encephalopathy

**Code also**, if applicable, associated disorders such as:

developmental disorders of scholastic skills (F81.x)

developmental disorder of speech and language (F80.x)

epilepsy, by specific type (G40.x)

intellectual disabilities (F70-F79)

other neurodevelopmental disorder (F88)

pervasive developmental disorders (F84.x)

**Chapter 10 Diseases of the Respiratory System**

**J13-J17 Code also:** If applicable, any associated condition such as: Abscess (J85.1) Aspiration pneumonia (J69.x)

**Chapter 21 Factors Influencing Health Status and Contact with Health Services**

**Z59.71** Insufficient health insurance coverage

Inadequate social insurance

Insufficient social insurance

No health insurance coverage

**Z59.72** Insufficient welfare support

Inadequate welfare support

**Z68.54** Body mass index [BMI] pediatric, 95th percentile for age to less than 120% of the 95th percentile for age

**Z68.55** Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than140% of the 95th percentile for age

**Z68.56** Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*Disclaimer\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The Tennessee Chapter of the American Academy of Pediatrics (TNAAP) is not affiliated with any other organization, vendor, or company.  The information contained herein is intended for educational purposes only, and any other use (including, without limitation, reprint, transmission or dissemination in whole or in part) is strictly prohibited. Although reasonable attempts have been made to provide accurate and complete information, neither the publisher nor any person associated with TNAAP warrant or guarantee the information contained herein is correct or applicable for any particular situation.  TNAAP will not undertake to update any information provided herein.  In all cases, the practitioner or provider is responsible for use of this educational material, and any information provided should not be a substitution for the professional judgment of the practitioner or provider.

Resources: *ICD-10-CM 2025*